P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL

• K. H. Kuo,
• R. F. Grace,
• E. J. van Beers,
• W. Barcellini,
• A. Glenthøj,
• S. Holzhauer,
• P. Patel,
• V. Beynon,
• J. Li,
• E. Zagadailov,
• H. Al-Samkari

Affiliations

K. H. Kuo

1 Division of Hematology, University of Toronto, Toronto, Canada

R. F. Grace

2 Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Harvard Medical School, Boston, United States of America

E. J. van Beers

3 Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Netherlands

W. Barcellini

4 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

A. Glenthøj

5 Department of Hematology, Rigshospitalet, Copenhagen, Denmark

S. Holzhauer

6 Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany

P. Patel

7 Agios Pharmaceuticals, Inc., Cambridge

V. Beynon

7 Agios Pharmaceuticals, Inc., Cambridge

J. Li

7 Agios Pharmaceuticals, Inc., Cambridge

E. Zagadailov

7 Agios Pharmaceuticals, Inc., Cambridge

H. Al-Samkari

8 Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America